Unknown

Dataset Information

0

Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer.


ABSTRACT: PURPOSE:Targeted therapies for cancer have accelerated the need for functional imaging strategies that inform therapeutic efficacy. This study assesses the potential of functional genetic screening to integrate therapeutic target identification with imaging probe selection through a proof-of-principle characterization of a therapy-probe pair using dynamic nuclear polarization (DNP)-enhanced magnetic resonance spectroscopic imaging (MRSI). EXPERIMENTAL DESIGN:CRISPR-negative selection screens from a public dataset were used to identify the relative dependence of 625 cancer cell lines on 18,333 genes. Follow-up screening was performed in hepatocellular carcinoma with a focused CRISPR library targeting imaging-related genes. Hyperpolarized [1-13C]-pyruvate was injected before and after lactate dehydrogenase inhibitor (LDHi) administration in male Wistar rats with autochthonous hepatocellular carcinoma. MRSI evaluated intratumoral pyruvate metabolism, while T2-weighted segmentations quantified tumor growth. RESULTS:Genetic screening data identified differential metabolic vulnerabilities in 17 unique cancer types that could be imaged with existing probes. Among these, hepatocellular carcinoma required lactate dehydrogenase (LDH) for growth more than the 29 other cancer types in this database. LDH inhibition led to a decrease in lactate generation (P < 0.001) and precipitated dose-dependent growth inhibition (P < 0.01 overall, P < 0.05 for dose dependence). Intratumoral alanine production after inhibition predicted the degree of growth reduction (P < 0.001). CONCLUSIONS:These findings demonstrate that DNP-MRSI of LDH activity using hyperpolarized [1-13C]-pyruvate is a theranostic strategy for hepatocellular carcinoma, enabling quantification of intratumoral LDHi pharmacodynamics and therapeutic efficacy prediction. This work lays the foundation for a novel theranostic platform wherein functional genetic screening informs imaging probe selection to quantify therapeutic efficacy on a cancer-by-cancer basis.

SUBMITTER: Perkons NR 

PROVIDER: S-EPMC7483881 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer.

Perkons Nicholas R NR   Johnson Omar O   Pilla Gabrielle G   Profka Enri E   Mercadante Michael M   Ackerman Daniel D   Gade Terence P F TPF  

Clinical cancer research : an official journal of the American Association for Cancer Research 20200604 17


<h4>Purpose</h4>Targeted therapies for cancer have accelerated the need for functional imaging strategies that inform therapeutic efficacy. This study assesses the potential of functional genetic screening to integrate therapeutic target identification with imaging probe selection through a proof-of-principle characterization of a therapy-probe pair using dynamic nuclear polarization (DNP)-enhanced magnetic resonance spectroscopic imaging (MRSI).<h4>Experimental design</h4>CRISPR-negative select  ...[more]

Similar Datasets

| S-EPMC3196845 | biostudies-literature
| S-EPMC6929980 | biostudies-literature
| S-EPMC10540701 | biostudies-literature
| S-EPMC7922065 | biostudies-literature
| S-EPMC6825593 | biostudies-literature
| S-EPMC8625430 | biostudies-literature
| S-EPMC4670036 | biostudies-literature
| S-EPMC6287312 | biostudies-literature
| S-EPMC3775930 | biostudies-literature
| S-EPMC10467409 | biostudies-literature